Response to imatinib as a function of target kinase expression in recurrent glioblastoma

BACKGROUND: Despite some progress in the treatment of glioblastoma, most patients experience tumor recurrence. Imatinib mesylate, a tyrosine kinase inhibitor of platelet derived growth factor receptor-alpha and -beta, c-fms, c-kit, abl and arg kinase (imatinib targets), has been shown to prevent tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassler, Marco Ronald, Vedadinejad, Mariam, Flechl, Birgit, Haberler, Christine, Preusser, Matthias, Hainfellner, Johannes Andreas, Wöhrer, Adelheid, Dieckmann, Karin Ute, Rössler, Karl, Kast, Richard, Marosi, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320134/
https://www.ncbi.nlm.nih.gov/pubmed/25674429
http://dx.doi.org/10.1186/2193-1801-3-111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320134/
https://www.ncbi.nlm.nih.gov/pubmed/25674429
http://dx.doi.org/10.1186/2193-1801-3-111

Ejemplares similares